RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Quintiles announced today that it has sold its minority interest in Invida, an Asia Pacific commercial solutions joint venture, to the Italy-based Menarini Group, which is acquiring Invida in its entirety. Invida was formed in 2006 by Quintiles; The Zuellig Group; and TLS Beta Pte. Ltd., an Asia investment company.
Invida provides biopharmaceutical product sales support in 13 markets in Asia Pacific; the Menarini Group is a privately held top-50 global biopharmaceutical company.
“As a result of this opportunity, we will pursue strategic expansion of our commercial solutions in Asia that are integrated with Quintiles’ global systems, capabilities and expertise, and optimize the breadth and depth of our offerings across our Commercial, Clinical, Capital and Consulting groups,” said Rich Pilnik, President of Global Commercial Solutions, Quintiles. “We will continue to build from our existing Commercial business in Japan, where Quintiles is the market leader in outsourced commercialization solutions.”
Quintiles Global Services presence in Asia is augmented by its expansion into key emerging markets. This year, Global Commercial Solutions launched services in Russia. It also is investing and growing in Turkey and Egypt, and aggressively pursuing growth strategies in Africa, the Middle East and Latin America.
About Global Commercial Solutions
With about 7,000 employees on five continents, the Commercial group leverages the full suite of Quintiles’ sales, marketing, clinical, consulting and capital services to provide innovative, customized commercial solutions to partners throughout the biopharmaceutical industry. Global Commercial Solutions was formerly Innovex, which now functions solely under the Quintiles name. For more information, please visit www.quintiles.com/commercial-services.
About Quintiles
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of more than 20,000 engaged professionals in 60 countries works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.